BAL 30072

Drug Profile

BAL 30072

Alternative Names: BAL0030072; BAL30072

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Basilea Pharmaceutica
  • Class Antibacterials; Monobactams; Pyridones
  • Mechanism of Action Beta lactamase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Gram-negative infections

Highest Development Phases

  • Phase I Gram-negative infections
  • Discontinued Respiratory tract infections

Most Recent Events

  • 15 Aug 2016 BAL 30072 is still in phase I trials for Gram-negative-infections (In volunteers) in Switzerland (IV, Infusion)
  • 15 Aug 2016 Discontinued for Respiratory tract infections in Switzerland (Inhalation)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Gram-negative-infections(In volunteers) in Switzerland (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top